関連する実験動画
Updated: Sep 9, 2025
07:18
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
8.5K
アルツハイマー病におけるVDAC1媒介の自閉症のダウンレギュレーションによるウロリチンAの神経保護効果
Bensi Zhang1, Xiujun Zhang1, Waleephan Treebupachatsakul2
1Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Department of Human Anatomy, College of Basic Medicine, Dali University, Dali, Yunnan 671000, PR China.
Acta histochemica
|September 2, 2025
まとめ
ウロリチンA (UA) は認知機能を改善し,アルツハイマー病においてアミロイドβ (Aβ) を減少させる.
科学分野:
- 神経科学
- 細胞生物学
- 薬理学について
背景:
- アミロイドベータ (Aβ) の蓄積は,アルツハイマー病 (AD) の病理を駆動する.
- 腸内代謝物質であるウロリチンA (UA) は神経保護効果を示しています.
- ADにおけるUAの正確なメカニズムはほとんど不明である.
研究 の 目的:
- アルツハイマー病 (AD) モデルにおけるウロリチンA (UA) の神経保護効果を調査する.
- アミロイドベータ (Aβ) 病理に対するUAの作用の基礎となる分子メカニズムを解明する.
- 認知機能,自己消化,重要な信号伝達経路に対する UAの影響を調査する.
主な方法:
- APP/PS1マウスにおける認知評価のためのモリス水迷宮試験
- Aβ収納とタンパク質発現 (VDAC1,AMPK,PI3K/AKT/mTOR,オートファギーマーカー) を分析するために,免疫光とウェスタン・ブロッティングを行う.
- Aβ 損傷したニューロン細胞系 (N2a,PC12) の細胞活性アッセイ (CCK8)
主要な成果:
- UA治療はAPP/PS1マウスにおける認知機能の有意な改善とAβ負荷の減少をもたらした.
- UAはオートファギーを活性化し,PI3K/AKT/mTORとAMPKの信号伝達経路を調節した.
- UAは,電圧依存アニオンチャンネル1 (VDAC1) をダウン調節し,その観測効果にとって決定的なプロセスである.
結論:
- ウロリチンA (UA) は,アルツハイマー病 (AD) 病理学に対する重要な神経保護性を持っています.
- UAのメカニズムは,VDAC1のダウンレギュレーション,PI3K/ AKT/ mTORの阻害,およびAMPKの活性化により,自己死を促進する.
- これらの発見は,ADの潜在的な治療薬としてUAを強調しています.
関連する概念動画
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
01:27Autophagy
4.6K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.6K